Abstract

BackgroundEndoscopic retrograde cholangio-pancreatography (ERCP) is commonly performed in the management of pancreatic and biliary disease. Duodenoscopes are specialized endoscopes used to perform ERCP, and inherent to their design, a high rate of persistent bacterial contamination exists even after automated reprocessing and disinfection. Consequently, in recent years, ERCP has been associated with infection transmission, leading to several fatal patient outbreaks. Due to increasing fears over widespread future duodenoscope-related outbreaks, regulatory bodies have called for alterations in the design of duodenoscopes. A duodenoscope has recently been developed that employs a disposable cap. This novel design theoretically eliminates the mechanism behind persistent bacterial contamination and infection transmission. However, there are no data demonstrating persistent bacterial contamination rates, technical success rates, or clinical outcomes associated with these duodenoscopes.MethodsA parallel arm randomized controlled trial will be performed for which 520 patients will be recruited. The study population will consist of consecutive patients undergoing ERCP procedures for any indication at a high-volume tertiary care centre in Calgary, Alberta, Canada. Patients will be randomized to an intervention group, that will undergo ERCP with a novel duodenoscope with disposable cap, or to a control group who will undergo ERCP with a traditional duodenoscope. Co-primary outcomes will include persistent bacterial contamination rates (post automated reprocessing) and ERCP technical success rates. Secondary outcomes include clinical success rates, overall and specific early and late adverse event rates, 30-day mortality and healthcare utilization rates, procedure and reprocessing times, and ease of device use.DiscussionThe ICECAP trial will answer important questions regarding the use of a novel duodenoscope with disposable cap. Specifically, persistent bacterial contamination, technical performance, and relevant clinical outcomes will be assessed. Given the mortality and morbidity burden associated with ERCP-related infectious outbreaks, the results of this study have the capacity to be impactful at an international level.Trial registrationThis trial was registered on clinicaltrials.gov (NCT04040504) on July 31, 2019.

Highlights

  • Endoscopic retrograde cholangio-pancreatography (ERCP) is commonly performed in the management of pancreatic and biliary disease

  • The ICECAP trial will answer important questions regarding the use of a novel duodenoscope with disposable cap

  • Given the mortality and morbidity burden associated with ERCP-related infectious outbreaks, the results of this study have the capacity to be impactful at an international level

Read more

Summary

Methods

Study design and setting This protocol (version 7.0) was written and reported according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) recommendations [16, 17], and a SPIRIT checklist is provided in Supplemental 1 This is a consecutive parallel arm phase IV RCT which will assess 1) the persistent bacterial contamination rate (PBC) of a duodenoscope with a disposable elevator cap (DEC) versus a traditional duodenoscope and 2) the technical and clinical. The adjudicators will review redacted and de-identified procedure reports for each study patient, and determine the presence or absence of technical success of the overall procedure based on a set of a priori definitions (Tables 1 and 2). Statistical considerations For primary outcome 1, a 2018 study [12] demonstrated a PBC rate of over 20% after standard duodenoscope disinfection, but with limited sample size for Pentax scopes. The results of this study are potentially impactful on an international level

Discussion
Background
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call